AR and pachyonychia congenita: Furthermore, larger cohorts of ADT and non-ADT patients are also recommended to obtain stronger evidence and the effect of other drugs that are currently used in castration-resistant PC (e.g. Enzalutamide or Abiraterone) which target the AR or the testosterone synthesis, respectively, should also be analyzed in prospective studies.